U.S. Markets open in 2 hrs 29 mins

Gilead Sciences

Gilead Sciences (GILD) got a positive revenue from the FDA for its new hepatitis C drug. On Fri. experts will vote to recommend the drug's approval. Shares rose 1.4%.